Press Releases
BOSTON, July 25, 2019 /PRNewswire/ -- Intervention Insights announces the appointment of Chet Burrell as its Executive Chairman to support the continued growth of its distinct, precision diagnostic platform
Read more...25 July 2019
NASDAQ: CORV TSX: CORVNDA Seeks Approval for Brinavess for the Treatment of Recent Onset Atrial Fibrillation; PDUFA Date Set for December 24, 2019Company Also Reports Certain Preliminary Financial Results for Second Quarter 2019 VANCOUVER, July 25, 2019 /PR
Read more...MISSISSAUGA, ON, July 25, 2019 /PRNewswire/ - ADVANZ PHARMA Corp. ("ADVANZ PHARMA" or "the Company") (TSX:ADVZ), a global pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today commented on the issuance by the UK Competition and Markets Author
Read more...BURLINGTON, ON, July 25, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. ("RDT") (CSE: DOSE) announced today
Read more...25 July 2019
REDWOOD CITY, Calif., July 25, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that U.S. District Judge Colm Connolly, in the District of Delaware, granted Nevro's motion f
Read more...BOSTON and PARIS, July 25, 2019 /PRNewswire/ -- PathMaker Neurosystems Inc. ("PathMaker"), a clinical-stage bioelectronic medicine company developing breakthrough non-invasive
Read more...BOSTON, July 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that the first patient has been dosed in the Company's 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transm
Read more...DUBLIN, July 25, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2019. "Our second quarter results reflect the gro
Read more...CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dick
Read more...25 July 2019
BRUSSELS, July 25, 2019 /PRNewswire/ --– Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER1) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted2 +11%, +7% CER) Underlying profitability (rEBITDA3) was € 724 million (-9%, -1%
Read more...